Applied Therapeutics Inc banner

Applied Therapeutics Inc
NASDAQ:APLT

Watchlist Manager
Applied Therapeutics Inc Logo
Applied Therapeutics Inc
NASDAQ:APLT
Watchlist
Price: 0.103 USD 3% Market Closed
Market Cap: $14.9m

Applied Therapeutics Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Applied Therapeutics Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Applied Therapeutics Inc
NASDAQ:APLT
Other Items
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Items
-$5.4B
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Other Items
-$4.2B
CAGR 3-Years
-35%
CAGR 5-Years
21%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
Other Items
-$85m
CAGR 3-Years
74%
CAGR 5-Years
55%
CAGR 10-Years
33%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Items
-$507.8m
CAGR 3-Years
-63%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Items
$584.6m
CAGR 3-Years
N/A
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

Applied Therapeutics Inc
Glance View

Market Cap
14.9m USD
Industry
Biotechnology

Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).

APLT Intrinsic Value
HIDDEN
Show

See Also

What is Applied Therapeutics Inc's Other Items?
Other Items
0 USD

Based on the financial report for Sep 30, 2025, Applied Therapeutics Inc's Other Items amounts to 0 USD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett